Open AccessMeasurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy
Author(s) -
Tomino Yasuhiko,
Suzuki Shigenobu,
Imai Hirokazu,
Saito Takao,
Kawamura Tetsuya,
Yorioka Noriaki,
Harada Takashi,
Yasumoto Yuichiro,
Kida Hiroshi,
Kobayashi Yutaka,
Endoh Masayuki,
Sato Hidetoshi,
Saito Kensuke
Publication year - 2000
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/1098-2825(2000)14:5<220::aid-jcla4>3.0.co;2-2
Subject(s) - nephropathy , medicine , renal biopsy , biopsy , immunoglobulin a , glomerulonephritis , gastroenterology , immunology , immune system , endocrinology , kidney , immunoglobulin g , diabetes mellitus
Abstract The levels of serum IgA and C3 in patients with IgA nephropathy were determined using international standard serum (IFCC/CRM470) in a multicenter trial in Japan. The ratio of serum IgA to C3 (serum IgA/C3 ratio) without any information from renal biopsy was used for the diagnosis of IgA nephropathy. Three hundred and six patients with IgA nephropathy and other glomerular diseases, and 418 healthy adults were examined. The new diagnostic standardized criterion in patients with IgA nephropathy, obtained by nephelometric immune assay based on the international reference preparation CRM470, was 315 mg/dl. The serum IgA/C3 ratio was a more useful marker for distinguishing IgA nephropathy from non‐IgA nephropathy together with serum IgA levels. This suggests that the measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. J. Clin. Lab. Anal. 14:220–223, 2000. © 2000 Wiley‐Liss, Inc.